# Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

> **NCT00083525** · PHASE1 · COMPLETED · sponsor: **Heidelberg Pharma AG** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** WX-UK1 in combination with Capecitabine

## Key facts

- **NCT ID:** NCT00083525
- **Lead sponsor:** Heidelberg Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2008-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083525, "Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00083525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*